Subscribe To
Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific
– ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action – BRYAN, Texas and ...
November 1, 2023, 12:24 pm
Aptevo to present at bio-europe conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing nov...
November 1, 2023, 7:45 am
Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...
October 31, 2023, 10:12 am
Xencor: a mid-stage clinical company with falling losses
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...
October 20, 2023, 11:02 pm
Akari therapeutics to present at emerging growth conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced t...
September 27, 2023, 8:00 am
Lava therapeutics to participate in the h.c. wainwright 25th annual global investment conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focu...
September 6, 2023, 7:11 am
Pfizer gets fda accelerated approval for multiple myeloma treatment
A Pfizer Inc. PFE, +0.52% treatment for relapsed or refractory multiple myeloma has received accelerated approval from the U.S. Food and Drug Administ...
August 14, 2023, 2:40 pm
Genmab: epkinly's approval not big enough needle-mover (neutral)
Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma...
June 29, 2023, 10:05 am
Immunocore holdings: unlocking the immune system's hidden potential
Immunocore Holdings is a leading biotech firm with a promising pipeline of T cell receptor-based bispecific...
June 11, 2023, 3:49 am
Celldex therapeutics presents positive preclinical data from tslp/scf bispecific antibody program cdx-622 at immunology2023™
HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical data from CDX-622, the Company�...
May 15, 2023, 12:01 pm
Context therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024
Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's c...
May 11, 2023, 10:08 am
Context therapeutics says ctim-76 abstract accepted for presentation at aacr annual meeting, will host webinar
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 ...
April 16, 2023, 3:01 am
Merus: dutch drug developer with an interesting platform
Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of ...
April 4, 2023, 9:28 am
Context therapeutics announces pipeline update with fy 2022 financial results
Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway...
March 23, 2023, 8:10 am
Context therapeutics says ctim-76 abstract accepted for presentation at aacr annual meeting
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 ...
March 15, 2023, 9:16 am
Xencor to present preclinical data from novel xmab® cd28 bispecific antibody programs at the american association for cancer research annual meeting 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin...
March 14, 2023, 4:31 pm
Context therapeutics announces manufacturing agreement with lonza for bispecific antibody targeting claudin 6 positive cancers
Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech...
January 9, 2023, 9:03 am
Ngm bio gives presentation featuring preclinical characterization of ngm936 at 2022 ash annual meeting
–NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent ...
December 13, 2022, 12:00 am
Biopharma co.’s shares triple in value on us$5b license deal
Source: Streetwise Reports (12/7/22) Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-lic...
December 8, 2022, 1:30 pm
Context therapeutics finds lead clinical development candidate for cancer treatment in ctim-76
Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, a...
November 29, 2022, 10:52 am